Compare Dynatrace Inc. Common Stock (DT) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dynatrace Inc. Common Stock vs Hinge Health Inc. Class A Common Stock — how do they compare? Dynatrace Inc. Common Stock trades at $64.1 (market cap $18.37B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: Dynatrace Inc. Common Stock is far larger — about 2.2× Hinge Health Inc. Class A Common Stock's market cap, and Dynatrace Inc. Common Stock is more actively traded (11,065,883 versus 1,624,526). Which is the better fit depends on your goals — on Pluang, investors hold Dynatrace Inc. Common Stock for 3 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| DT | HNGE | |
|---|---|---|
Market Cap | $18.37B | $8.47B |
Volume | 11,065,883 | 1,624,526 |
Sector | Technology | Health |
52-Week High | $65.25 | $105.14 |
52-Week Low | $32.36 | $31.17 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $17.43B | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dynatrace (DT) trades at $64.46, down 1.21% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported robust revenue growth to $1.70B in 2025 and has consistently beaten earnings estimates, though its valuation ratios like a P/E of 128.94 are elevated. Recent developments include achieving FedRAMP certification and completing the acquisition of Arize, enhancing its AI observability platform.
The outlook is positive given strong analyst support (85.71% buy ratings) and a consensus price target of $62.44, though risks include high valuation sensitivity and projected net income decline in 2026. Earnings growth and federal market expansion are key catalysts, but investors should monitor execution against lofty expectations.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dynatrace Inc. Common Stock
Dynatrace provides an observability, security, and automation platform for cloud and IT environments. Its platform integrates data such as logs, metrics, and traces to help organizations monitor digital systems.
Read more on DT →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
